CD276 and cancer: For example, anti-B7-H3 monoclonal antibodies can significantly inhibit the growth of renal cell carcinoma and bladder cancer [16]; chimeric antigen receptor (CAR) T cells targeting B7-H3 have a significant therapeutic effect on malignant meningiomas [17]; and an antibody–drug conjugate targeting B7-H3 has obvious antitumor activity against malignant tumors such as breast cancer and melanoma [18].